je.st
news
Tag: mercks
Mercks Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus
2016-06-13 16:30:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Data in Patients with Type 1 and Type 2 Diabetes Presented for the First Time at the 76 th Scientific Sessions of the American Diabetes Association KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from two Phase 3 studies evaluating MK-1293, Mercks investigational, follow-on biologic* insulin glargine candidate for the treatment of people with type 1 and type 2 diabetes. Language: English Contact: MerckMedia:Doris Li, 908-246-5701Kristen Drake, 908-334-4688orInvestor:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Mercks ZEPATIER (Elbasvir and Grazoprevir) Showed Superiority on Efficacy and Safety Endpoints Compared to Sofosbuvir Plus Peginterferon and Ribavirin Treatment Regimen in Phase 3 Trial
2016-04-14 07:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Results From C-EDGE Head-to-Head Study in Patients with Chronic Hepatitis C Genotypes 1 or 4 Infection Presented at The International Liver Congress 2016 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from C-EDGE Head-to-Head, the companys comparative, Phase 3, open-label clinical trial evaluating the efficacy and safety of ZEPATIER (elbasvir and grazoprevir) 50mg/100mg tablets versus a regimen of sofosbuvir 400mg tablets plus peginterferon and ribavirin (pegIFN/RBV) in treatment-nave and pegIFN/RBV treatment-experienced patients with chronic hepatitis C (HCV) genotype (GT) 1 or GT4 infect Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Sarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: in
safety
treatment
trial
Mercks Investigational Once-Daily Formulation of ISENTRESS (raltegravir) Meets Primary and Secondary Endpoints in Pivotal Phase 3 Study
2016-02-22 14:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Results to be Presented at Future Medical Meeting, and Regulatory Submissions Planned for 2016 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced top-line results from the companys Phase 3 pivotal trial, ONCEMRK. ONCEMRK is evaluating an investigational once-daily formulation of ISENTRESS (raltegravir), known as raltegravir 600 mg (to be given as 2 x 600 mg once-daily), for previously untreated HIV-1 infected adults. Language: English Contact: For MerckMedia:Pamela Eisele, 267-305-3558orCarmen de Gourville, 267-305-4195orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: study
primary
phase
secondary
FDA Approves Mercks Single-Dose EMEND (fosaprepitant dimeglumine) for Injection, in Combination with Other Antiemetic Agents, for the Prevention of Delayed Nausea and Vomiting in Adults Receiving Moderately Emetogenic Chemotherapy (MEC)
2016-02-04 14:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. First and Only Intravenous NK1 Receptor Antagonist Approved in the U.S. for Use in MEC KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for single-dose EMEND (fosaprepitant dimeglumine) for injection, Mercks substance P/neurokinin-1 (NK1) receptor antagonist, in combination with other antiemetic medicines, for the prevention of delayed nausea and vomiting in adults receiving initial and repeat courses of moderately emetogenic chemotherapy (MEC). Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558An Phan, 908-255-6325orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: combination
agents
receiving
adults
World Health Organization to Review Mercks Investigational Ebola Vaccine for Emergency Use Assessment and Listing
2015-12-23 14:30:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the application for Emergency Use Assessment and Listing (EUAL) for the companys investigational Ebola Zaire vaccine, V920 (rVSVG-ZEBOV-GP, live attenuated), has been accepted for review by the World Health Organization (WHO). Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Skip Irvine, 215-652-6059orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: world
health
review
listing
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] next »